Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alto Neuroscience (ANRO) Payables (2023 - 2026)

Alto Neuroscience has reported Payables over the past 4 years, most recently at $3.4 million for Q1 2026.

  • Quarterly results put Payables at $3.4 million for Q1 2026, up 143.42% from a year ago — trailing twelve months through Mar 2026 was $3.4 million (up 143.42% YoY), and the annual figure for FY2025 was $1.9 million, up 18.94%.
  • Payables reached $3.4 million in Q1 2026 per ANRO's latest filing, up from $1.9 million in the prior quarter.
  • Across five years, Payables topped out at $3.4 million in Q1 2026 and bottomed at $1.1 million in Q4 2023.
  • Median Payables over the past 4 years was $1.9 million (2024), compared with a mean of $2.0 million.
  • The largest annual shift saw Payables tumbled 42.62% in 2025 before it soared 143.42% in 2026.
  • Over 4 years, Payables stood at $1.1 million in 2023, then surged by 47.02% to $1.6 million in 2024, then rose by 18.94% to $1.9 million in 2025, then soared by 79.39% to $3.4 million in 2026.
  • Business Quant data shows Payables for ANRO at $3.4 million in Q1 2026, $1.9 million in Q4 2025, and $2.1 million in Q3 2025.